Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Join thousands of traders who make more informed decisions withourpremium features. Real-time quotes, advancedvisualizations, backtesting, and much more.
Based on 3 Wall Street analysts offering 12 month price targets for Curis in the last 3 months. The average price target is $20.50 with a high forecast of $26.00 and a low forecast of $15.00. The average price target represents a 34.69% change from the last price of $15.22.
Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics or the treatment of cancer.
Based on 23 Wall Street analysts offering 12 month price targets for Broadcom in the last 3 months. The average price target is $1,572.68 with a high forecast of $1,720.00 and a low forecast of $1,430.00. The average price target represents a 17.01% change from the last price of $1,344.07.
The average price target is $80.47 with a high forecast of $112.00 and a low forecast of $30.00. The average price target represents a 32.64% change from the last price of $60.67.
In the current month, CEG has received 11 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CEG average Analyst price target in the past 3 months is $173.38.
The Editas Medicine stock prediction for 2025 is currently $ 6.00, assuming that Editas Medicine shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 13.23% increase in the EDIT stock price.
What is the iBio stock forecast? The iBio stock forecast for tomorrow is $ 1.626887, which would represent a -6.51% loss compared to the current price. In the next week, the price of IBIO is expected to decrease by -19.91% and hit $ 1.393718.
Introduction: My name is Neely Ledner, I am a bright, determined, beautiful, adventurous, adventurous, spotless, calm person who loves writing and wants to share my knowledge and understanding with you.
We notice you're using an ad blocker
Without advertising income, we can't keep making this site awesome for you.
